Nanexa Shares Surge Over 150% After Licensing Deal With Novo Nordisk

Shares in Nanexa, a small Swedish drug-delivery company, surged by more than 150% after the firm announced a licensing agreement with Novo Nordisk, the Danish pharmaceutical giant behind the weight-loss drug Wegovy.

The deal centers on injectable drug-delivery technology, according to the announcement, though specific financial terms of the agreement, including its total value or royalty structure, were not detailed in initial reporting.

Nanexa's stock price move reflects investor enthusiasm for companies with ties to the rapidly growing market for GLP-1 receptor agonist drugs such as Wegovy and Ozempic, which have driven a wave of dealmaking across the pharmaceutical and biotech sectors as companies seek to expand manufacturing capacity, improve drug delivery methods, and secure partnerships with larger players.

Novo Nordisk, one of the world's most valuable pharmaceutical companies, has faced growing competition in the obesity and diabetes drug market, including from US rival Eli Lilly, and has pursued a series of licensing and supply agreements to strengthen its production and delivery capabilities.

As a microcap stock, Nanexa's shares are subject to high volatility, and the scale of the rally underscores how sensitive smaller companies in the sector can be to news of partnerships with major pharmaceutical firms.